Crocs Surges 25% on Earnings Day as Short Sellers Retreat

CROX heads into its Q3 2026 earnings release having already delivered the day's most dramatic price move in the footwear sector.

The stock closed at $150.26 on October 29, up 25.5% on the day and 24.2% on the week, a move that stands in stark contrast to every close peer. DECK added less than 0.3% on the day. BIRK, CPRI and SHOO each fell. ZGN and LEVI gained, but by low single digits. Whatever drove buyers into Crocs, it was company-specific, not a sector-wide tailwind. Short sellers have read the same signal: short interest has fallen 8.1% over the past week and 17.6% over the past month, dropping to 8.9% of the free float. The borrow market reinforces the picture. Availability is ample at nearly 399% of current short interest, meaning roughly four shares are available to lend for every one already borrowed, and cost to borrow remains negligible at 0.53%. There is no squeeze pressure and no crowded short position. Options positioning is equally calm: the put/call ratio of 1.04 is marginally below its 20-day average of 1.05, well within the year's normal range.

The analyst community moved quickly after the close. Needham's Tom Nikic raised his target from $150 to $190 while maintaining a Buy rating. That single move is notable because $150 was already at the top of consensus before the stock's surge, and the revised $190 now sits above the current mean target of $148.92, which will be dragged higher as other desks react. Barclays had already upgraded to Overweight in mid-October with a $139 target. The bull case centres on stabilising North America DTC trends, a wholesale restocking cycle, international strength, and the possibility that HEYDUDE finally returns to growth in the second half. Bears had argued the core Crocs brand peaked after years of exceptional growth, that HEYDUDE's turnaround lacked evidence, and that management's own Q1 guidance implied revenue and margin declines. The print the company is releasing today is the first hard test of which narrative holds.

The institutional register does not flash an obvious activist angle. No 13D filer is on record. FMR trimmed its stake slightly in an August amendment, Vanguard entities hold positions consistent with passive mandates, and there is no 13D-style agitator with a public thesis. More telling on the insider side is the pattern from the summer: CEO Andrew Rees sold roughly $3.4 million of stock in early August at prices around $138 to $140, then two directors, Thomas Smach and Beth Kaplan, made open-market purchases in September at prices between $109 and $124. Neither group appears to have anticipated the October rally: the directors bought as the stock retreated and the CEO sold into prior strength. The net insider position over 90 days is a sale of about $3.5 million, though the director purchases add a modest contrarian note.

The earnings release will put numbers to a debate that has been almost entirely about direction: whether the Crocs brand stabilisation is real, whether HEYDUDE has turned, and whether the margin structure can absorb continued investment spending. Today's price action has already priced in a significant positive surprise before a single figure is reported.